The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


News Update

Biotech Collaborates to Advance Psychedelics Use in Cancer, Other Applications

News Update
  ()
Revive Therapeutics enters an agreement with PharmaTher, a specialty psychedelics pharmaceutical firm. read more >

Precision BioSciences & Eli Lilly Partner to Develop In Vivo Therapies for Genetic Disorders

  ()
Precision BioSciences shares traded 13% higher after the company reported it is partnering with Eli Lilly & Co. to develop in vivo therapies for genetic disorders with an initial focus on Duchenne's muscular dystrophy and two other undisclosed gene targets. read more >

Corcept Therapeutics Shares Rise 25% on Favorable U.S. Patent Office Ruling

  ()
Shares of Corcept Therapeutics reached a new 52-week high after the firm reported that the U.S. Patent Trial and Appeals Board affirmed that all claims pertaining to its U.S. Patent No.10,195,214 are valid. read more >

Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering

  ()
Kodiak Sciences shares reached a new 52-week high after the company announced the pricing of a $560.9 million public offering of its common stock. The report came one day after the firm advised it had completed enrollment of its Phase 2b/3 Pivotal DAZZLE Study of KSI-301 in patients with wet age-related macular degeneration. read more >

Lexicon Shares Rise 40% upon Achieving Primary Endpoints in Two Phase 3 Heart Failure Studies

  ()
Shares of Lexicon Pharmaceuticals traded higher after the company published results from the Phase 3 SOLOIST and SCORED trials showing that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits. read more >

Psychedelic Company Expected to Begin Trading Nov. 18

Reverse Takeover
  ()
Delic Corp., a thought leader in psychedelics, will trade on the Canadian Securities Exchange. read more >

Moderna Shares Get a Boost from Phase 3 COVID-19 Vaccine Trial Data Demonstrating 94.5% Efficacy

  ()
Moderna shares traded 10% higher to a new 52-week high after the company reported its COVID-19 vaccine candidate, mRNA-1273, met its primary endpoint in the first interim analysis of the Phase 3 COVE Study by achieving an efficacy rate of 94.5%. read more >
News Update

Life Sciences Firm Completes Development of Dissolvable Oral Psilocybin

News Update
  ()
Revive Therapeutics reported that it has developed an oral thin-film strip psilocybin product with doses ranging from 1 to 20 milligrams. read more >

Urovant Sciences Shares Double on Sumitovant Biopharma Buyout Offer

  ()
Shares of Urovant Sciences traded 93% higher to a new 52-week high after the company reported that it entered into a definitive agreement to be acquired by Sumitovant Biopharma for $16.25 per share in cash. read more >
News Update

Biotech Involved in COVID-19, Neurodegenerative Diseases Reports Q3/20 Results

News Update
  ()
ProMIS Neurosciences formed two new joint ventures, one for developing tests for the detection, diagnosis and monitoring of Alzheimer's disease, and the second for serological assays for antibodies to the SARS-CoV-2 virus. read more >
News Update

Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December

News Update
  ()
Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020. read more >
News Update

Biotech Comments on FDA Advisory Committee Recommendation of Not Licensing Alzheimer's Drug

News Update
  ()
ProMIS Neurosciences, which is developing its own therapeutics for this disease, weighs in on the committee's conclusions regarding Biogen's aducanumab. read more >

Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial

  ()
Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer. read more >

Biopharma Posts 'Impressive' Q3/20 Sales Amid Pandemic

Research Report
  ()
Paratek Pharmaceuticals' recent and future revenue are discussed in an H.C. Wainwright & Co. report. read more >

Pfizer and BioNTech Announce Extremely Positive Phase 3 COVID-19 Vaccine Trial Data; Production of 1.3 Billion Doses in 2021 Planned

  ()
Pfizer shares traded 9% higher to a new 52-week high price after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection. The company is making plans to produce up to 1.3 billion vaccine doses in 2021. read more >

Glaukos Shares Pressured Higher After Firm Reports 11% Rise in Q3 Revenue

  ()
Shares of Glaukos Corp. traded 9% higher after the company reported Q3/20 financial results that included an 11% YoY increase in glaucoma and corneal health net sales. read more >

U.S. Biotech Developing Cancer Therapeutics Has 'Deep Pipeline'

Research Report
  ()
ImmunoGen's broad pipeline that "could support long-term growth" is discussed in an H.C. Wainwright & Co. report. read more >

Supernus Pharma Shares Trade Up 21% on 52% Increase in Q3 YoY Revenue

  ()
Shares of Supernus Pharmaceuticals traded higher after the company reported financial results for Q3/20 that included a 52% increase in total revenues versus the same period in 2019. read more >
News Update

Multinational Phase 2b/3 COVID-19 Study Approved to Continue

News Update
  ()
Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy. read more >
News Update

Biotech Expects Interim Analysis Data from Phase 3 COVID-19 Study by Year-End

News Update
  ()
Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial. read more >

Mirati Therapeutics' Shares Rise 12.5% on Positive Data from Cancer Studies

  ()
Mirati Therapeutics' shares reached a new 52-week high after the company reported preliminary data for Adagrasib (MRTX849) demonstrated durable anti-tumor activity in its non-small cell lung cancer and colorectal cancer studies. read more >
News Update

Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month

News Update
  ()
ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic. read more >
News Update

Biotech Secures Supplier of Psilocybin, Other Psychedelics

News Update
  ()
Revive Therapeutics will use these products in future studies and clinical trials. read more >

Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial

  ()
Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder. read more >

BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals

  ()
Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction. read more >
Showing Results: 1 to 25 of 120 Next

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"SCOT is a bargain and Buy at current trading levels." ❭
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"New targets keep popping up due to CBR's exploration at Cuiu Cuiu." ❭
– Brien Lundin, Gold Newsletter (Jefferson Financial)
"GSV identified the best oxide intercepts ever at the Pinion deposit." ❭
– Andrew Mikitchook, M Partners
"MAG's attributable production in Q3/20 was 173 Koz." ❭
– Ryan Thompson, BMO Capital Markets
"PVG delivered another strong quarter in Q3/20." ❭
– Andrew Mikitchook, M Partners